对淋巴瘤进行双特异性抗体治疗
Genevieve M Gerhard1, Gottfried von Keudell1
1330 Brookline Ave, Boston, MA, 02215, USA.
Best practice & research. Clinical haematology
|March 12, 2025
概括
双特异性抗体为B细胞非霍奇金细胞提供了一个有希望的新疗法.
科学领域:
- 血液学和瘤学研究
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 在过去的十年中,B细胞非霍奇金淋巴瘤 (B-NHL) 治疗方法取得了重大进展.
- 双特异性抗体已经成为B-NHL的关键现成治疗选择.
- 扩散性大B细胞淋巴瘤 (DLBCL) 是评估这些新疗法的首要重点.
研究的目的:
- 审查B-NHL中双特异抗体的演变和当前状态,特别是DLBCL.
- 为了比较与这些新兴疗法相关的疗效,耐受性和挑战.
- 讨论未来的潜力,并优化临床试验设计进行比较分析.
主要方法:
- 对B-NHL的已批准和正在研究的两种特异性抗体进行文献审查.
- 对临床试验数据的分析,重点关注结果和毒性.
- 与其他治疗类别对双特异性抗体的比较评估.
主要成果:
- 双特异性抗体代表了B-NHL的快速发展的治疗类.
- 这些药物显示出作为有效,易于获得的治疗选择的希望.
- 目前正在进行的研究旨在完善对它们的益处和风险的理解.
结论:
- 双特异性抗体是B-NHL治疗的重要发展,特别是DLBCL.
- 优化临床试验设计对于比较结果和毒性至关重要.
- 确保适当的患者选择和治疗顺序是最大限度地提高安全性和疗效的关键.
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Hybridoma Technology
13.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.9K
Special Features of Adaptive Immunity
703
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
703
B Cell Activation and Differentiation
1.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


